Dentsply Sirona (XRAY)
(Delayed Data from NSDQ)
$27.69 USD
-0.09 (-0.32%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $27.68 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.69 USD
-0.09 (-0.32%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $27.68 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong performance in the Technologies & Equipment business.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
DENTSPLY SIRONA's (XRAY) Preliminary FY22 Sales Meet Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) preliminary results meet market expectation. While certain product categories are driving growth, macro headwinds continue to hurt the top line.
Why Is Dentsply (XRAY) Up 1% Since Last Earnings Report?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) third-quarter results benefit from the Technologies & Equipment business.
What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect strong performance in the Technologies & Equipment business.
Analysts Estimate Cardinal Health (CAH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
DexCom and Papa John's International have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
DexCom and Papa John's International are part of the Zacks Bull and Bear of the Day article.
3 Stocks From the Growing Digital Orthodontic Space in Focus
by Urmimala Biswas
The orthodontic treatment market has experienced substantial recovery, primarily owing to the easing of restrictions and mass opening up of the economy in 2022.
The Cooper Companies (COO) Lags Q3 Earnings Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of -0.31% and 1.44%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA (XRAY) Falls After Nasdaq's Delinquency Notice
by Zacks Equity Research
The Nasdaq exchange issues a notice to DENTSPLY SIRONA (XRAY) for filing delinquency from the exchange and for non-compliance with the Nasdaq Listing Rules. Shares fall.
Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 57.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA (XRAY) Up on Strong Q2 Preliminary Results
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) preliminary second-quarter 2022 results reflect the normalizing business, aided by product launches and pricing adjustments. Shares rise.
AmerisourceBergen (ABC) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
AmerisourceBergen (ABC) delivered earnings and revenue surprises of 1.95% and 1.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Buy DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
Is McKesson (MCK) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Is Dentsply (XRAY) Up 6.2% Since Last Earnings Report?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DENTSPLY SIRONA (XRAY) Reports Weak Q1 Preliminary Results
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) preliminary first-quarter 2022 results reflect weakness in segments.
SmileDirectClub (SDC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
SmileDirectClub (SDC) delivered earnings and revenue surprises of -11.76% and 10.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Becton Dickinson (BDX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.71% and 3.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for May 3rd
by Zacks Equity Research
ADT, XRAY, and BGSF have been added to the Zacks Rank #5 (Strong Sell) List on May 3, 2022.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.
Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.